Acurx Pharmaceuticals Q1 net loss narrows as expenses fall

Acurx Pharmaceuticals

12/05/2026 12:39

Overview

US biopharmaceutical developer's Q1 net loss narrowed yr/yr, EPS at -0.62

R&D and G&A expenses declined in Q1 due to lower manufacturing and legal costs

Company raised $3.1 mln in Q1 and closed direct offering to fund clinical trials

Outlook

Company says cash resources are sufficient to fund exploratory clinical trial in recurrent CDI

Acurx plans to advance ibezapolstat to Phase 3 international trials for acute CDI, subject to financing

Company awaits FDA clarification on one-trial approval standard, which may affect clinical development plans

Result Drivers

LOWER OPERATING COSTS - Decrease in R&D and G&A expenses due to reduced manufacturing, consulting, and legal costs

ADDITIONAL FUNDING - Company raised $3.1 mln in Q1 and closed a direct offering to support clinical trials

Company press release: ID:nPn8sqH9ka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.62


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $20.50, about 840.4% above its May 11 closing price of $2.18

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)